| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/26/2006 | EP1649865A1 Use of osteogenic proteins for the preparation of a pharmaceutical composition for repairing a defect locus in a non articular cartilage tissue of a mammal |
| 04/26/2006 | EP1649862A1 Agent for preventing and curing pathological states associated with endorphin deficiency in organism |
| 04/26/2006 | EP1649746A1 MSH5 ablated mice and uses therefor |
| 04/26/2006 | EP1649041A2 Multimeric oxidoreductases |
| 04/26/2006 | EP1649036A1 Method for producing cyclic molecules |
| 04/26/2006 | EP1649019A2 Improved inhibitor nucleic acids |
| 04/26/2006 | EP1649018A2 Sp1 and sp3 targeted cancer therapies and therapeutics |
| 04/26/2006 | EP1649017A1 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer |
| 04/26/2006 | EP1649005A2 P450 oxygenases and methods of use |
| 04/26/2006 | EP1649001A2 Antibodies and uses thereof |
| 04/26/2006 | EP1648998A2 Specific binding agents to hepatocyte growth factor |
| 04/26/2006 | EP1648938A1 Bcl-2 splicing variants |
| 04/26/2006 | EP1648934A2 Pharmaceutical composition comprising cyclic somatostatin analogues |
| 04/26/2006 | EP1648933A1 Long lasting insulin derivatives and methods thereof |
| 04/26/2006 | EP1648931A2 Novel multifunctional cytokines |
| 04/26/2006 | EP1648926A1 Glut-1 as a receptor for htlv envelopes and its uses |
| 04/26/2006 | EP1648925A1 Bicyclic peptide imaging agents |
| 04/26/2006 | EP1648924A2 Dipeptide transglutaminase inhibitors and methods of using the same |
| 04/26/2006 | EP1648923A1 Spatially-defined macrocycles incorporating peptide bond surrogates |
| 04/26/2006 | EP1648922A1 Spatially-defined macrocyclic compounds useful for drug discovery |
| 04/26/2006 | EP1648918A2 Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
| 04/26/2006 | EP1648917A2 Agonist polypeptide of receptor for zot and zonulin |
| 04/26/2006 | EP1648913A2 Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| 04/26/2006 | EP1648910A2 Antisense modulation of stearoyl-coa desaturase expression |
| 04/26/2006 | EP1648520A1 Compounds and methods for downregulating the effects of tgf-beta |
| 04/26/2006 | EP1648514A2 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 04/26/2006 | EP1648503A2 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases |
| 04/26/2006 | EP1648497A2 Compositions and methods for selective dissolution of nascent intravascular blood clots |
| 04/26/2006 | EP1648496A1 Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment |
| 04/26/2006 | EP1648495A2 Compositions comprising gastrin compounds and their use in diabetes |
| 04/26/2006 | EP1648494A2 Novel anti-angiogenetic agent and its use, in particular in cancer treatment |
| 04/26/2006 | EP1648493A2 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| 04/26/2006 | EP1648492A2 A novel antiproliferative factor and methods of use |
| 04/26/2006 | EP1648491A1 Use of xmp-629 for the treatment of acne |
| 04/26/2006 | EP1648490A2 Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity |
| 04/26/2006 | EP1648489A2 Treatment or prevention of damage due to radiation exposure |
| 04/26/2006 | EP1648488A2 Human mast cell-expressed membrane protein |
| 04/26/2006 | EP1648487A2 Immunotherapeutics for biodefense |
| 04/26/2006 | EP1648486A2 Use of a pak inhibitor for the treatment of a joint disease |
| 04/26/2006 | EP1648485A2 Formulation for a protein pharmaceutical without added human serum albumin (hsa) |
| 04/26/2006 | EP1648481A1 Viral vectors |
| 04/26/2006 | EP1648478A1 Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation |
| 04/26/2006 | EP1648477A2 Injection of bone marrow-derived cells and medium for angiogenesis |
| 04/26/2006 | EP1648474A2 Methods and pharmaceutical compositions for healing wounds |
| 04/26/2006 | EP1648459A1 Sir2 regulation |
| 04/26/2006 | EP1648428A2 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer |
| 04/26/2006 | EP1648387A2 Fugetactic proteins, compositions and methods of use |
| 04/26/2006 | EP1648379A2 Vaccines using pattern recognition receptor-ligand:lipid complexes |
| 04/26/2006 | EP1648232A2 Method of treating hit patients with argatroban |
| 04/26/2006 | EP1499731A4 Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
| 04/26/2006 | EP1448281A4 Therapeutic coating for an intravascular implant |
| 04/26/2006 | EP1361894B1 Use of a polyfunctional active substance mixture as an antagonist against harmful substances contained in tobacco smoke acting as a health protecting agent during smoking |
| 04/26/2006 | EP1326634B1 Vaccine composition comprising an antigen and a peptide having adjuvant properties |
| 04/26/2006 | EP1313509B1 Treatment of tumors with acetylenes disubstituted with an heteroaromatic group and a substituted thiochromanyl group in combination with other anti-tumor agents |
| 04/26/2006 | EP1294689B1 Preparation method of a novel beta crystalline form of perindopril tert-butylamine salt |
| 04/26/2006 | EP1244702B1 Process for isolation of osteopontin from milk |
| 04/26/2006 | EP1218514B1 Designing immunogens |
| 04/26/2006 | EP1187918B1 Tek antagonists |
| 04/26/2006 | EP1185666B1 Hyaluronidase from the hirudinaria manillensis, isolation, purification and recombinant method of production |
| 04/26/2006 | EP1155121B1 Compositions and methods for modulating serum cholesterol |
| 04/26/2006 | EP1059353B1 Novel calpain and dna encoding the same |
| 04/26/2006 | EP1056779B1 Method for producing a factor viii/von willebrand factor complex |
| 04/26/2006 | EP1053313B1 Optimized antisense oligonucleotides complementary to dna methyltransferase sequences |
| 04/26/2006 | EP1009829B1 Adipocyte-specific protein homologs |
| 04/26/2006 | EP1002108B1 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
| 04/26/2006 | EP0966536B1 Factor x analogues with a modified protease cleavage site |
| 04/26/2006 | EP0848614B1 Isolation of microdomains of caveolae and gpi-anchored proteins |
| 04/26/2006 | EP0784686B1 Herpes simplex virus glycoprotein d variants |
| 04/26/2006 | EP0773997B1 Htk ligand |
| 04/26/2006 | CN1764723A Interleukin-18 mutants, their production and use |
| 04/26/2006 | CN1764722A Cyclic AMP response element activator proteins and uses related thereto |
| 04/26/2006 | CN1764481A Cellular preparation |
| 04/26/2006 | CN1764475A Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
| 04/26/2006 | CN1764473A Use of alum and a Th1 immune response inducing adjuvant for enhancing immune responses |
| 04/26/2006 | CN1764471A Use of chemokine receptor agonists for stem cell transplantation |
| 04/26/2006 | CN1764470A Use of erythropoietin in stroke recovery |
| 04/26/2006 | CN1764469A Papanicolau staining process |
| 04/26/2006 | CN1764457A Combination therapy for the treatment of Alzheimer's disease |
| 04/26/2006 | CN1764375A Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease |
| 04/26/2006 | CN1764372A Autologous or homologous coagulant produced from anticoagulated whole blood |
| 04/26/2006 | CN1763203A Gene recombinant human cytomegalovirus fusion protein pp150/MDBP, preparation process and application thereof |
| 04/26/2006 | CN1763195A Human Nanog gene and its encoded protein and application |
| 04/26/2006 | CN1763190A Production method for recombinant cytoglobin and uses thereof |
| 04/26/2006 | CN1763188A Snake venom thrombin-like enzyme and its encoding gene and application |
| 04/26/2006 | CN1763185A Low-toxicity staphylokinase mutant, its preparation process and uses |
| 04/26/2006 | CN1763184A Novel bifunctional molecule of RGD staphylokinase, its preparation process and application |
| 04/26/2006 | CN1763106A Antiviral fusion protein and its coding gene and uses |
| 04/26/2006 | CN1763097A Polypeptide variants with altered effector function |
| 04/26/2006 | CN1763093A Survivin mutant containing HIV transduction structural area and its preparation method and uses |
| 04/26/2006 | CN1763092A Antibiotic peptide and its coding sequence and uses |
| 04/26/2006 | CN1763087A Towel gourd seed ribosome deactivated protein and its coding gene and uses |
| 04/26/2006 | CN1763086A ANK protein for controlling fungus colony growth and pathogenicity and its coding gene and utilization |
| 04/26/2006 | CN1763083A Cyclopentapeptide extraction method and its uses in preparing anti-tumour medicine |
| 04/26/2006 | CN1763081A Antibiotic dipeptide and its chemical modifier, its preparation method and uses |
| 04/26/2006 | CN1763027A Novel ascorbic acid compounds, methods of synthesis and application use thereof |
| 04/26/2006 | CN1762494A Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 04/26/2006 | CN1762492A CD40 binding molecules and CTL peptides uses in pharmic composition for treating tumors |
| 04/26/2006 | CN1762491A Use of BCG as adjuvant of active protein activating cytotoxic T-lymphocyte |
| 04/26/2006 | CN1762490A Tumor antigen based on products of the tumor suppressor gent WT1 |
| 04/26/2006 | CN1762489A Tf-SOD conjugate and its preparation process |